Samantha Stokes

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract PO5-22-10: Are contralateral prophylactic mastectomy rates impacted by ASBrS guidelines to offer germline genetic testing to all patients with breast cancer? Results from a large, prospective, single-institution cohort

  Cancer Research · 2024-05-02 · 1 citations

• Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

  npj Breast Cancer · 2024-04-16

• ASO Visual Abstract: Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions

  Annals of Surgical Oncology · 2024-02-16

• Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions

  Annals of Surgical Oncology · 2024-01-23 · 1 citations

• Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer

  Journal of Clinical Oncology · 2024-01-08 · 33 citations

• Abstract LB074: Towards the next generation cancer dependency map

  Cancer Research · 2023-04-14

• Abstract 5229: Pathogenic germline mutations and risk of multiple myeloma

  Cancer Research · 2023-04-04 · 2 citations

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Figure from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing ProgramPreprint

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Figure from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing ProgramPreprint

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Supplementary Table from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing Program

  2023-03-31

• Data from Identification and Management of Pathogenic Variants in <i>BRCA1</i>, <i>BRCA2</i>, and <i>PALB2</i> in a Tumor-Only Genomic Testing ProgramPreprint

  2023-03-31